STOCK TITAN
  1. Home
  2. XSPRAY

XSPRAY Stock Price, News & Analysis

XSPRAY
Published by Stock Titan Data refreshed

What Changed

Company Description

This page collects what Stock Titan holds for XSPRAY, including price data and latest news.

Stock Performance

Chart
—
-
-
-
Performance 1 year
-
Market Cap
-
Shares outstanding

Latest News

View All
—

Xspray Pharma Submits XS003 to the FDA – The Company’s Second Product Candidate from the HyNap Platform

—

Xspray Pharma Signs License Agreement with Handa Therapeutics – to Receive up to Double-Digit Royalty on Handa’s Net Proceeds

clinical trial
—

Xspray Pharma Announces Positive FDA Meeting and Plans for Dasynoc NDA Resubmission

fda approval
—

Scientific Article in Leading Journal Endorses Xspray Pharma's HyNap Technology

—

Xspray Pharma’s XS003 Study Shows Matching Bioavailability to Tasigna at More than a 50% Lower Dose

—

Xspray to present data at ASCO highlighting frequent comedication of PPIs with TKIs in CML-patients and greater than expected negative effects on the bioavailability of crystalline dasatinib

conferences
—

FDA Accepts Xspray Pharma’s NDA-resubmission for Dasynoc® – PDUFA Date set to 31 July 2024

clinical trial fda approval
—

Xspray Pharma’s XS003 Achieves Superior Bioavailability Milestone, Matching TASIGNA® at Reduced Dosage

—

DASYNOC™ Uptake into the Blood Remains Consistent When Taken with Omeprazole, Whereas SPRYCEL® Uptake is Significantly More Impaired than Previously Understood

—

Xspray Pharma Partners with EVERSANA® for the U.S. Launch and Commercialization of its Lead Product, Dasynoc (XS004) for the Treatment of Chronic Myeloid Leukemia (CML) and Acute Lymphatic Leukemia (ALL)

partnership

XSPRAY has 10 recent news articles. Key topics include clinical trial, fda approval, conferences, partnership. View all XSPRAY news →

SEC Filings

No SEC filings available for XSPRAY.